PTO Form 1581 (Rev 9/2005)
`
`OMB No. 0651-0054 (Exp. 10/31/2017)
`
`Request for Extension of Time to File a Statement of Use
`(15 U.S.C. Section 1051(d))
`
`Input Field
`
`SERIAL NUMBER
`
`LAW OFFICE ASSIGNED
`
`MARK SECTION
`
`MARK
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`LITERAL ELEMENT
`
`OWNER SECTION
`
`NAME
`
`STREET
`
`CITY
`
`STATE
`
`ZIP/POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`EMAIL
`
`The table below presents the data as entered.
`
`Entered
`
`85350709
`
`LAW OFFICE 116
`
`BASAGLAR
`
`YES
`
`YES
`
`BASAGLAR
`
`Eli Lilly and Company
`
`Lilly Corporate Center
`
`Indianapolis
`
`Indiana
`
`46285
`
`United States
`
`317-276-9624
`
`317-276-1919
`
`trademarks@lilly.com
`
`GOODS AND/OR SERVICES SECTION
`
`INTERNATIONAL CLASS
`
`005
`
`CURRENT IDENTIFICATION
`
`Pharmaceutical preparations, namely, pharmaceutical preparations for the
`diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety
`disorders, atherosclerosis, autoimmune diseases and disorders, blood
`disorders, bone and skeletal diseases and disorders, cancer, cardiovascular
`diseases, central nervous system diseases and disorders, cholesterol
`disorders, cystic fibrosis, dementia, dermatological diseases and disorders,
`diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal
`diseases and disorders, hormonal diseases and disorders, inflammation and
`inflammatory diseases and disorders, kidney diseases and disorders, liver
`diseases and disorders, metabolic diseases and disorders, migraines, muscle
`diseases and disorders, neurodegenerative diseases and disorders,
`neurological disorders, obesity, pain, pancreatic diseases and disorders,
`psychiatric disorders, reproductive system diseases and disorders, sleep
`disorders, urological disorders; antidepressants
`
`GOODS OR SERVICES DELETED FROM THE
`APPLICATION
`
`obesity
`
`Pharmaceutical preparations, namely, pharmaceutical preparations for the
`
`

`

`GOODS OR SERVICES FOR WHICH APPLICANT
`HAS A CONTINUED BONA FIDE INTENTION, AND
`IS ENTITLED, TO USE
`
`EXTENSION SECTION
`
`EXTENSION NUMBER
`
`ONGOING EFFORT
`
`ALLOWANCE MAIL DATE
`
`STATEMENT OF USE
`
`PAYMENT SECTION
`
`NUMBER OF CLASSES
`
`SUBTOTAL AMOUNT
`
`TOTAL AMOUNT
`
`SIGNATURE SECTION
`
`SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`DATE SIGNED
`
`SIGNATORY'S PHONE NUMBER
`
`FILING INFORMATION
`
`SUBMIT DATE
`
`TEAS STAMP
`
`diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety
`disorders, atherosclerosis, autoimmune diseases and disorders, blood
`disorders, bone and skeletal diseases and disorders, cancer, cardiovascular
`diseases, central nervous system diseases and disorders, cholesterol
`disorders, cystic fibrosis, dementia, dermatological diseases and disorders,
`diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal
`diseases and disorders, hormonal diseases and disorders, inflammation and
`inflammatory diseases and disorders, kidney diseases and disorders, liver
`diseases and disorders, metabolic diseases and disorders, migraines, muscle
`diseases and disorders, neurodegenerative diseases and disorders,
`neurological disorders, pain, pancreatic diseases and disorders, psychiatric
`disorders, reproductive system diseases and disorders, sleep disorders,
`urological disorders; antidepressants
`
`3
`
`product or service research or development
`
`12/27/2011
`
`NO
`
`1
`
`150
`
`150
`
`/reljr44/
`
`Robert E. Lee, Jr.
`
`Assistant General Patent Counsel
`
`04/25/2013
`
`317 276 9624
`
`Thu Apr 25 10:37:34 EDT 2013
`
`USPTO/ESU-XX.XX.XXX.XX-20
`130425103734068412-853507
`09-500d087b2c2837a9c8fe71
`819cb7ec1ce64792383c6c46f
`ad7049fbffdf9a2bf9-DA-846
`1-20130424180817058344
`
`

`

`PTO Form 1581 (Rev 9/2005)
`
`OMB No. 0651-0054 (Exp. 10/31/2017)
`
`To the Commissioner for Trademarks:
`
`MARK:(cid:160)BASAGLAR
`SERIAL NUMBER:(cid:160)85350709
`
`SOU Extension Request
`(15 U.S.C. Section 1051(d))
`
`The applicant, Eli Lilly and Company, having an address of
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)Lilly Corporate Center
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)Indianapolis, Indiana 46285
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)United States
`requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. (cid:160)(cid:160) The Notice of Allowance
`mailing date was 12/27/2011.
`
`For International Class 005:
`Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use
`disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and
`disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia,
`dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal
`diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders,
`metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders,
`obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological
`disorders; antidepressants
`
`This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for
`this specific class; these goods/services are permanently deleted from this application: obesity
`
`For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection
`with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification
`mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or
`in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
`specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders,
`Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders,
`cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological
`diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and
`disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases
`and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic
`diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
`
`This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with
`each of those goods/services covered by the extension request: product or service research or development
`
`A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
`
`Declaration
`
`The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under
`18 U.S.C. Section 1001, and that such willful false statements may jeopardize the validity of the form or any resulting registration, declares that
`he/she is properly authorized to execute this form on behalf of the applicant; he/she believes the applicant to be the owner of the
`trademark/service mark sought to be registered; and that all statements made of his/her own knowledge are true; and that all statements made on
`information and belief are believed to be true.
`
`

`

`Signature: /reljr44/(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)Date Signed: 04/25/2013
`Signatory's Name: Robert E. Lee, Jr.
`Signatory's Position: Assistant General Patent Counsel
`Signatory's Phone: 317 276 9624
`
`RAM Sale Number: 85350709
`RAM Accounting Date: 04/25/2013
`
`Serial Number: 85350709
`Internet Transmission Date: Thu Apr 25 10:37:34 EDT 2013
`TEAS Stamp: USPTO/ESU-XX.XX.XXX.XX-20130425103734068
`412-85350709-500d087b2c2837a9c8fe71819cb
`7ec1ce64792383c6c46fad7049fbffdf9a2bf9-D
`A-8461-20130424180817058344
`
`

`

`TEAS ROUTING SHEET
`
`To: INTENT TO USE UNIT
`
`Work Loc: INTENT TO USE SECTION
`
`Doc Type: Extension Request for SOU
`
`Serial Number: 85350709
`
`Mark: BASAGLAR
`
`Mail Date: 2013/04/25
`
`Examiner Number: 73703
`
`Examiner Name:
`CARROLL, DORITT
`
`L.O. Assigned: LAW OFFICE 116
`
`Special Instruction(s):
`
`Transaction
`
`Fee
`Code
`
`Transaction
`Date
`
`Fee per
`Class
`
`Total
`Number
`of Classes @
`
`Extension Request for SOU
`
`7004
`
`20130425
`
`$150
`
`1
`
`$150
`
`